

33. Rice DP, Hodgson TA: The value of human life revisited. *Am J Public Health* 1982; 72: 536-538
34. Thompson MS, Read JL, Liang M: Feasibility of willingness-to-pay measurement in chronic arthritis. *Med Decis Making* 1984; 4: 195-215
35. Mishan EJ: *Cost-benefit Analysis*, 3rd Ed, London, George Allen & Unwin, 1992
36. Shelling TC, Chase SB: The life you save may be your own. In *Problems in Public Expenditure Analysis*, Washington D.C., The Brookings Institution, 1968
37. Eisenberg JM, Schulman KA, Glick H, Koffler H: Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom BL, ed, *Pharmacoepidemiology*, Chichester, Wiley, 1994; 469-493
38. Schulman KA, Linas BP: Pharmacoeconomics: state of the art in 1997. *Annu Rev Public Health* 1997; 18: 529-548
39. Drummond M: Economic analysis alongside clinical trials: problems and potential. *J Rheumatol* 1995; 22: 1403-1407
40. Gulati SC, Bitran JD: Cost-effectiveness analysis: sleeping with an enemy or a friend? *J Clin Oncol* 1995; 13: 2152-2154
41. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE Jr, Simes J, Topol EJ: Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. *N Engl J Med* 1995; 332: 1418-1424
42. Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. *CMAJ* 1992; 146: 473-481
43. Evans D, Freund D, Dittus R, Robertson J, Henry D: *The Use of Economic Analysis as a Basis for Inclusion of Pharmacoeconomic Products on the Pharmaceutical Benefits Scheme*. Department of Health, Housing and Community Services, Canberra, Commonwealth of Australia, 1990
44. Fayers PM, Hand DJ: Generalisation from phase III clinical trials: survival, quality of life, and health economics. *Lancet* 1997; 350: 1025-1027
45. Sackett DL, Haynes RB, Guyatt CH, Tugwell P: *Clinical Epidemiology: A Basic Science for Clinical Medicine*, Boston, Little Brown, 1991
46. Schulman KA, Llana T, Yabroff KR: Economic assessment within the clinical development program. *Med Care* 1996; 34: DS89-DS95
47. O'Brien BJ, Drummond MF, Labelle RJ, Willan A: In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. *Med Care* 1994; 32: 150-163
48. Stiller CA: Centralised treatment, entry to trials and survival. *Br J Cancer* 1994; 70: 352-362
49. Stiller CA: Survival of patients with cancer. *BMJ* 1989; 299: 1058-1059
50. Schulman KA, Buxton M, Glick H, Sculpher M, Guzman G, Kong J, Backhouse M, Mauskopf J, Bell L, Eisenberg JM: Results of the economic evaluation of the first study. A multinational prospective economic evaluation. *Int J Technol Assess Health Care* 1996; 12: 698-713
51. Schulman KA, Dorsainvil D, Yabroff KR, DiCesare J, Felser J, Eisenberg JM, Glick HA, the IL-3 BMT Study Team: Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone-marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. *Bone Marrow Transplant* 1998; 21: 607-614
52. Hays RD, Sherbourne CD, Bozzette SA: Pharmacoeconomics and quality of life research beyond the randomized clinical trial. In: Spilker B, ed, *Quality of Life and Pharmacoeconomics in Clinical Trials*, 2nd Ed, Philadelphia, Lippincott-Raven, 1996; 155-159
53. Cunningham WE, Bozzette SA, Hays RD, Kanouse DE, Shapiro MF: Comparison of health-related quality of life in clinical trial and nonclinical trial human immunodeficiency virus cohorts. *Med Care* 1995; 33: AS15-AS25